Recent studies also found that AML patients with IDH2 mutations were associated with improved overall survival [15, 16] and tend to be correlated with a favorable prognosis compared with those with wt-IDH2 [17–19], suggesting a possibility that the wild-type enzyme could potentially provide certain metabolic advantage to leukemia cells and promote AML progression with poor outcome. Here, IDH2 is linked to leukemia.